Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability

Completed · Phase 2

Conditions studied: Huntington's Disease

In brief

The purpose of this clinical trial is to extend the Pre-Crest-X study to further assess the long-term safety and tolerability of up to 30 grams daily creatine in individuals at-risk for Huntington's Disease (HD) and to assess whether biomarkers responsive to creatine in symptomatic individuals are informative in premanifest individuals over a longer duration.

Key facts

Study ID

NCT01411163

Run by

Massachusetts General Hospital

People needed

24

Starts

2010-04-01

Expected to finish

2013-05-01

Last updated by the study team

2014-02-10

Who can join

Age: 26 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individuals who have completed the Pre-CREST Study.
• Individuals capable of providing independent informed consent and complying with trial procedures.

You may not qualify if…

• Clinical evidence of unstable medical or psychiatric illness in the investigator's judgment.
• Additional eligibility criteria apply.

Where it is running

• Massachusetts General Hospital — Charlestown, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.